Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.

breast cancer comorbidity electronic health records patient reported outcome measures symptom assessment

Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 18 09 2023
received: 01 06 2023
accepted: 07 10 2023
pubmed: 30 10 2023
medline: 30 10 2023
entrez: 30 10 2023
Statut: ppublish

Résumé

Comorbidities and symptoms in metastatic breast cancer patients impact treatment decisions and influence prognosis and quality of life. The objective of this study is to examine the concordance between physician documentation and patient reports of comorbidities and symptoms to understand their comparative effectiveness. New patients with metastatic breast cancer completed an electronic intake survey assessing patient health history and symptoms. Physician documentation across 54 comorbidities and 42 symptoms was abstracted from notes for the corresponding clinic visits between November 2016 and March 2020. Concordance between patient reports and medical records for each condition and hazards ratios for each patient versus physician reported comorbidity and symptom were assessed. A total of 168 patients were included in the analysis (age, median = 56 years, range = 29-86 years; 131 white [78.9%]). Twenty-three of 54 comorbidities had a moderate to high level of agreement between patients and physicians (κ ≥ 0.40). Physicians documented higher numbers of comorbidities that can be objectively measured which also had higher concordance (e.g., diabetes [κ = 0.83] and hypertension [κ = 0.79]) while patients reported higher numbers of comorbidities that are more subjective which also had lower concordance (anxiety [κ = 0.30], GERD [κ = 0.36]). One physician-documented and two patient-reported comorbidities were significantly associated with survival (p < 0.05). Only 2 of 42 symptoms had a moderate to high level of agreement between patients and physicians. One physician-documented and nine patient-reported symptoms were significantly associated with decreased survival (p < 0.05). Agreement between patients' and physicians' reporting of comorbidities varies substantially, and patient reports can complement physician documentation. Physicians significantly underreported symptoms versus patients; thus, concordance was also low. Multiple patient-reported symptoms were predictive of survival; thus, incorporating them can provide more informative estimates of predicted survival.

Sections du résumé

BACKGROUND BACKGROUND
Comorbidities and symptoms in metastatic breast cancer patients impact treatment decisions and influence prognosis and quality of life. The objective of this study is to examine the concordance between physician documentation and patient reports of comorbidities and symptoms to understand their comparative effectiveness.
METHODS METHODS
New patients with metastatic breast cancer completed an electronic intake survey assessing patient health history and symptoms. Physician documentation across 54 comorbidities and 42 symptoms was abstracted from notes for the corresponding clinic visits between November 2016 and March 2020. Concordance between patient reports and medical records for each condition and hazards ratios for each patient versus physician reported comorbidity and symptom were assessed.
RESULTS RESULTS
A total of 168 patients were included in the analysis (age, median = 56 years, range = 29-86 years; 131 white [78.9%]). Twenty-three of 54 comorbidities had a moderate to high level of agreement between patients and physicians (κ ≥ 0.40). Physicians documented higher numbers of comorbidities that can be objectively measured which also had higher concordance (e.g., diabetes [κ = 0.83] and hypertension [κ = 0.79]) while patients reported higher numbers of comorbidities that are more subjective which also had lower concordance (anxiety [κ = 0.30], GERD [κ = 0.36]). One physician-documented and two patient-reported comorbidities were significantly associated with survival (p < 0.05). Only 2 of 42 symptoms had a moderate to high level of agreement between patients and physicians. One physician-documented and nine patient-reported symptoms were significantly associated with decreased survival (p < 0.05).
CONCLUSION CONCLUSIONS
Agreement between patients' and physicians' reporting of comorbidities varies substantially, and patient reports can complement physician documentation. Physicians significantly underreported symptoms versus patients; thus, concordance was also low. Multiple patient-reported symptoms were predictive of survival; thus, incorporating them can provide more informative estimates of predicted survival.

Identifiants

pubmed: 37902219
doi: 10.1002/cam4.6632
pmc: PMC10709717
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20906-20917

Subventions

Organisme : Give Breast Cancer the Boot
Organisme : Safeway Foundation
Organisme : University of California Office of the President
ID : A114103

Informations de copyright

© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

JAMA Oncol. 2019 Mar 1;5(3):326-333
pubmed: 30629092
BMC Cancer. 2009 Apr 20;9:116
pubmed: 19379520
J Clin Aesthet Dermatol. 2019 Jan;12(1):16-23
pubmed: 30881572
Cancer Med. 2023 Nov;12(22):20906-20917
pubmed: 37902219
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
J Palliat Care. 1991 Summer;7(2):6-9
pubmed: 1714502
JAMA. 2004 May 26;291(20):2441-7
pubmed: 15161894
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Hypertension. 2012 Feb;59(2):205-11
pubmed: 22184319
Breast Cancer Res Treat. 2012 Aug;134(3):1327-35
pubmed: 22798157
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
J Clin Epidemiol. 2011 Mar;64(3):309-19
pubmed: 21147517
Epidemiology. 2002 May;13(3):340-6
pubmed: 11964937
Ann Oncol. 2015 Jul;26(7):1325-32
pubmed: 25605751
CA Cancer J Clin. 2016 Jul;66(4):337-50
pubmed: 26891458
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
J Thorac Oncol. 2019 Jun;14(6):1012-1020
pubmed: 30776447
J Am Coll Surg. 2002 Jan;194(1):8-13
pubmed: 11800343
Med Care. 1996 Jan;34(1):73-84
pubmed: 8551813
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Am J Manag Care. 2008 Aug;14(8):530-9
pubmed: 18690769
J Clin Oncol. 2004 Aug 1;22(15):3099-103
pubmed: 15284260
PLoS One. 2020 May 5;15(5):e0232752
pubmed: 32369514
JAMA Netw Open. 2020 Jun 1;3(6):e205867
pubmed: 32515797

Auteurs

Saumya Umashankar (S)

University of California, San Francisco, California, USA.

Amrita Basu (A)

University of California, San Francisco, California, USA.

Laura Esserman (L)

University of California, San Francisco, California, USA.

Laura Van't Veer (L)

University of California, San Francisco, California, USA.

Michelle E Melisko (ME)

University of California, San Francisco, California, USA.

Classifications MeSH